Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epacadostat + Nivolumab in advanced cancers
NCT02327078Phase 2Completed
- Sponsor
- Incyte
- Start
- Nov 2014
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label trial of epacadostat in melanoma, non-small cell lung cancer (NSCLC), squamous cell carcinoma of the head and neck (HNSCC) and 5 more (9 arms), sponsored by Incyte. Primary endpoints: Dose Limiting Toxicities at Day 42, Treatment-Emergent Adverse Events up to 39 months and 3 more. Started Nov 2014; status: completed.
02
Drugs
epacadostat
03
Conditions
melanomanon-small cell lung cancer (NSCLC)squamous cell carcinoma of the head and neck (HNSCC)colorectal cancer (CRC)ovarian cancer
Beyond the preview
Go deeper on NCT02327078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02327078.